Summary: GLP-1 receptor agonists, such as Ozempic and Wegovy, may drastically reduce behaviors linked to violence. Analyzing a 2025 survey of U.S. adults, researchers found that current GLP-1 use weakened the traditional link between high impulsivity and violent behavior by 62%, and softened the link between alcohol use and violence by 52%.
The findings suggest these metabolic medications function similarly to cognitive behavioral therapy by lengthening the psychological pathway between an aggressive impulse and physical action, highlighting a potential new frontier for public safety research.
Key Facts
- Behavioral Moderation: GLP-1 medications like Ozempic and Wegovy, primarily prescribed for diabetes and obesity, significantly alter psychological pathways linked to violent behavior.
- 62% Drop in Impulsive Action: The historical connection linking highly impulsive personality traits to physical violence was found to be 62% weaker in current GLP-1 users versus former users.
- Blunting Alcohol-Induced Violence: Current GLP-1 use was associated with a 52% weaker link between alcohol consumption and violent offenses, though this metric showed more variance in sensitivity testing.
- CBT-Like Neurological Mechanism: Neuroscientists note the drug functions much like cognitive behavioral therapy, effectively weakening the direct bridge from a sudden impulse to a physical reaction.
- Study Scope and Limitations: The research analyzed a 2025 sample of 7,521 American adults (focusing on 821 GLP-1 users) but remains observational, necessitating future longitudinal trials to prove definitive causation.
Source: Rutgers University
The use of GLP-1 medications commonly prescribed for weight loss or managing diabetes may have effects that extend beyond metabolic health, including on behaviors linked to violence, according to Rutgers researchers.
Their study, published in Criminology, examined whether the use of GLP-1 receptor agonist medications, such as Ozempic and Wegovy, influences violent criminal behavior among adults by moderating the effects of impulsivity and alcohol intake.
Researchers analyzed data from a 2025 survey of 7,521 U.S. adults and focused their primary analyses on 821 individuals who had ever used a GLP-1 medication. The study compared current GLP-1 users with former users and examined whether medication use changed the relationship between violent behavior, impulsivity and alcohol use. Violent behavior was measured using a validated self-reported offending scale assessing behaviors such as fighting, assault and robbery.
“The strongest finding in the study was that the well-established link between impulsivity and violent behavior was substantially weaker among current GLP-1 users compared to former users,” said Daniel Semenza, the lead author of the study as well as the director of research at the New Jersey Gun Violence Research Center at the Rutgers School of Public Health and an associate professor with the Rutgers School of Public Health.
“As GLP-1 drugs become increasingly widespread, it is important to understand all of their potential behavioral effects, including those relevant to public safety,” Semenza said.
Researchers found that higher impulsivity and alcohol use were strongly associated with violent behavior overall, but those relationships were significantly weaker among current GLP-1 users. The association between impulsivity and violent behavior was about 62% weaker among current users compared with former users. The relationship between alcohol use and violent behavior was about 52% weaker among current users, although those findings were less consistent across sensitivity analyses.
“Our findings are consistent with these medications working like cognitive behavioral therapy, weakening the path from impulse to action rather than eliminating impulsivity itself,” said Christopher Thomas, an assistant professor at Rutgers University-Camden and the coauthor of the study.
The study was observational and cross-sectional, meaning causal conclusions cannot be drawn, the researchers said. They emphasized the need for future longitudinal and experimental studies to determine whether GLP-1 medications reduce violence risk and to better understand the mechanisms involved.
Key Questions Answered:
A: GLP-1 receptors are not just located in the gut to control digestion; they are highly abundant in brain regions that regulate reward, dopamine signaling, motivation, and impulse control, such as the striatum and prefrontal cortex. By stabilizing these neural pathways, the medication alters how the brain processes rewards and immediate urges, which can quiet down compulsive drives, whether they are related to food, substances, or sudden behavioral outbursts.
A: Cognitive behavioral therapy teaches individuals to pause, identify an erratic or negative impulse, and choose not to act on it. The researchers discovered that GLP-1 drugs do not necessarily erase a person’s baseline impulsive personality or completely stop them from getting angry. Instead, the medication chemically mimics CBT by weakening the direct path from impulse to action, granting the brain a brief, protective pause to override a destructive reaction.
A: Not definitively. The Rutgers study was observational and cross-sectional, capturing a snapshot of data from a 2025 survey. Because it looks at data at a single point in time, it cannot conclusively prove that starting a GLP-1 drug causes a drop in violence. The researchers emphasize that rigorous, long-term clinical trials and longitudinal studies are required to track behavioral changes over time before making broad public policy claims.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this neuropharmacology and violence research news
Author: Patrice Harley
Source: Rutgers University
Contact: Patrice Harley – Rutgers University
Image: The image is credited to Neuroscience News
Original Research: Open access.
“GLP-1 receptor agonist use and violent crime among US adults” by Daniel C. Semenza, Christopher Thomas. Criminology
DOI:10.1111/1745-9125.70058
Abstract
GLP-1 receptor agonist use and violent crime among US adults
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a class of medications widely prescribed for diabetes and obesity, have exhibited emerging effects on substance use, reward processing, and impulse control. This study examines whether current GLP-1 RA use moderates established behavioral pathways to violent crime from impulsivity and alcohol use.
Data come from a 2025 nationally representative US survey (n = 7521; 821 lifetime GLP-1 RA users). Negative binomial regression models with overlap weighting compared current (n = 597) and former (n = 224) users on self-reported violent criminal behavior in the past year.
Although impulsivity and alcohol use were strongly associated with violent criminality, these associations were significantly weaker among current GLP-1 RA users (GLP-1 RA × impulsivity incidence rate ratio (IRR) = 0.38, p = 0.002; GLP-1 RA × alcohol use IRR = 0.48, p = 0.023). Robustness checks consistently supported the GLP-1 RA × impulsivity interaction, whereas less consistent support was found for the alcohol interaction.
Results suggest that GLP-1 RAs may attenuate widely documented behavioral risk mechanisms like impulsivity linked to aggression, pointing to novel biosocial hypotheses regarding pharmacological influences on violent criminality. Future longitudinal and experimental research should confirm these findings and test causal mechanisms.
